Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.

TitleIs Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
Publication TypeJournal Article
Year of Publication2021
AuthorsBattat R, Long MD
JournalAm J Gastroenterol
Volume116
Issue10
Pagination2029-2031
Date Published2021 10 01
ISSN1572-0241
KeywordsColitis, Drug Monitoring, Gastrointestinal Agents, Humans, Inflammatory Bowel Diseases, Tumor Necrosis Factor Inhibitors
Abstract

ABSTRACT: As a plethora of data emerges on therapeutic drug monitoring (TDM) of biologics in inflammatory bowel disease, guidance on its application is needed. In this literature review and consensus statement, the authors recommend reactive TDM for all biologics, summarize concentration targets, and provide guidance on TDM in various scenarios. Proactive TDM with tumor necrosis factor-antagonist monotherapy is recommended as an alternative to the combination of tumor necrosis factor-antagonists with immunomodulators. Although observational data support this approach, randomized controlled trials do not. We argue that there is considerable work left to be performed before embracing proactive TDM as an equivalent alternative to combination therapy in inflammatory bowel disease.

DOI10.14309/ajg.0000000000001500
Alternate JournalAm J Gastroenterol
PubMed ID34515666